Selecting a selective serotonin reuptake inhibitor: Clinically important distinguishing features

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 2, Issue 6, 2000, Pages 205-210

  Marken, Patricia A ^a   Stuart Munro, J ^a,b  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b Western Missouri Mental Health Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0242360060     PISSN: 15235998     EISSN: None     Source Type: Journal    
DOI: 10.4088/pcc.v02n0602     Document Type: Article

References (55)

1. Hays RD, Wells KB, Sherbourne CD, et al. Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses. Arch Gen Psychiatry 1995;52:11-19
2. Wells KB, Sherbourne CD. Functioning and utility for current health of patients with depression or chronic medical conditions in managed, primary care practices. Arch Gen Psychiatry 1999;56:897-904
3. Frasure-Smith N, Lesperance F, Juneau M, et al. Gender, depression, and one-year prognosis after myocardial infarction. Psychosom Med 1999;61: 26-37
4. Rovner BW. Depression and increased risk of mortality in the nursing home patient. Am J Med 1993;94:19S-22S
5. Penninx BW, Guralnik JM, Ferrucci L, et al. Depressive symptoms and physical decline in community-dwelling older persons. JAMA 1998;279: 1720-1726
6. Penninx BW, Geerlings SW, Deeg DJ, et al. Minor and major depression and the risk of death in older persons. Arch Gen Psychiatry 1999;56: 889-895
7. Preskorn SH. Outpatient Management of Depression: A Guide for the Primary-Care Practitioner. Caddo, Okla: Professional Communications; 1999
8. Ekselius L, von Knorring L, Eberhard G. A double-blind multicenter trial compatjrig^Sertr.aline and citalopram in patients with major depression treated in general practice. Int Clin Psychopharmacol 1997;12:323-331
9. Fava M, Amsterdam JD, Deltito JA, et al. A double-blind study of paroxetine, fluoxetine and placebo in outpatients with major depression. Ann Clin Psychiatry 1998;10:145-150
10. Aguglia E, Casacchia M, Cassano GB, et al. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol 1993;8:197-202
11. Patris M, Bouchard JM, Bougerol T, et al. Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase 3 trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacol 1996;11:129-136
12. De Wilde J, Spiers R, Mertens C, et al. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand 1993;87:141-145
13. Kiev A, Feiger A. A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients. J Clin Psychiatry 1997;58: 146-152
14. Cantrell R, Gillespie W, Altshuler L. Fluoxetine and sertraline dosages in major depression. Depress Anxiety 1999;9:78-82
15. Catterson ML, Preskorn SH. Pharmacokinetics of selective serotonin reuptake inhibitors: clinical relevance. Pharmacol Toxicol 1996;78:203-208
16. Dalhoff K, Almdal TP, Bjerrum K, et al. Pharmacokinetics of paroxetine in patients with cirrhosis. Eur J Clin Pharmacol 1991;41:351-354
17. Prozac (fluoxetine). Physicians' Desk Reference. Montvale, NJ: Medical Economics; 1999:924-928
18. Luvox (fluvoxamine). Physicians' Desk Reference. Montvale, NJ: Medical Economics; 1999:3121-3124
19. Paxil (paroxetine). Physicians' Desk Reference. Montvale, NJ: Medical Economics; 1999:3078-3083
20. Iribarne C, Picart D, Dreano Y, et al. In vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine. Fundam Clin Pharmacol 1998;12:194-199
21. Rasmussen BB, Nielsen TL, Brosen K. Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. Pharmacol Toxicol 1998;83: 240-245
22. von Moltke LL, Greenblatt DJ, Court MH, et al. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995;15:125-131
23. Jeppesen U, Rasmussen BB, Brosen K. Fluvoxamine inhibits the CYP2C19-catalytic bioactivation of chloroguanide. Clin Pharmacol Ther 1997;62:279-286
24. Xu ZH, Xie-HG, Zhou HH. In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine. Br J Clin Pharmacol 1996;42:518-521
25. Brosen K, Skjelbo E, Rasmussen BB, et al. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45:1211-1214
26. Skjelbo E, Brosen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992;34:256-261
27. Vandel S, Bertschy G, Baumann P, et al. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res 1995;31:347-353
28. Kashuba AD, Nafziger AN, Kearns GL, et al. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin Pharmacol Ther 1998;64:257-268
29. Schmider J, Greenblatt DJ, von Moltke LL, et al. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro studies of phenytoin p-hydroxylation. Br J Clin Pharmacol 1997;44;495-458
30. Belpaire FM, Wijnant P, Temmerman A, et al. The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors. Eur J Clin Pharmacol 1998;54:261-264
31. Avenoso A, Spina E, Campo G, et al. Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications. Pharmacol Res 1997;35:335-339
32. Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992;51:239-248
33. Gram LF, Hansen MG, Sindrup SH, et al. Citalopram: interaction studies with levomepromazine, imipramine, and lithium. Ther Drug Monit 1993;15:18-24
34. Jeppesen U, Gram LF, Vistisen K, et al. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996;51:73-78
35. Priskorn M, Sidhu JS, Larsen F, et al. Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol 1997;44:199-202
36. Kobayashi K, Yamamoto T, Chiba K, et al. The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4′-hydroxylase activity in human liver microsomes. Br J Clin Pharmacol 1995;40:481-485
37. Ozdemir V, Naranjo CA, Herrmann N, et al. The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline. J Clin Psychopharmacol 1998;18:55-61
38. Bhatara VS, Bandettini FC. Possible interaction between sertraline and tranylcypromine. Clin Pharm 1993;12:222-225
39. Tremaine LM, Wilner KD, Preskorn SH. A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. Clin Pharmacokinet 1997;32:31-36
40. Kurtz DL, Bergstrom RF, Goldberg MJ, et al. The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin Pharmacol Ther 1997;62:145-156
41. Solai LK, Mulsant BH, Pollock BG, et al. Effect of sertraline on plasma nortriptyline level in depressed elderly. J Clin Psychiatry 1997;58: 440-443
42. Alderman J, Preskorn SH, Greenblatt DJ, et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 1997;17:284-291
43. Sproule BA, Naranjo CA, Brenmer KE, et al. Selective serotonin reuptake inhibitors and CNS drug interactions: a critical review of the evidence. Clin Pharmacokinet 1997;33:454-471
44. Masand PS, Gupta S. Selective serotonin-reuptake inhibitors: an update. Harv Rev Psychiatry 1999;7:69-84
45. Stahl SM. Essential Psychopharmacology. 2nd ed. New York, NY: Cambridge University Press; 1999
46. Richelson E. Synaptic effects of antidepressants. J Clin Psychopharmacol 1996;16:1S-7S; discussion 7S-9S
47. Haffmans PM, Timmerman L, Hoogduin CA, for the LUCIFER Group. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. Int Clin Psychopharmacol 1996;11:157-164
48. Grimsley SR, Jann MW, Carter JG, et al. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther 1991;50:10-15
49. Pearson HJ. Interaction of fluoxetine with carbamazepine [letter]. J Clin Psychiatry 1990;148:1604-1605
50. Gidal BE, Anderson GD, Seaton TL, et al. Evaluation of the effect of fluoxetine on the formation of carabamazepine epoxide. Ther Drug Monit 1993;15:405-409
51. Gordon JB. SSRIs and St. John's wort: possible toxicity? [letter] Am Fam Physician 1998;57:950, 953
52. Skop BP, Finkelstein JA, Mareth TR, et al. The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease. Am J Emerg Med 1994;12:642-644
53. Lantz MS, Buchalter E, Giambanco V. St. John's wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol 1999;12:7-10
54. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998;44:77-87
55. Nurnberg HG, Thompson PM, Hensley PL. Antidepressant medication change in a clinical treatment setting: a comparison of the effectiveness of selective serotonin reuptake inhibitors. J Clin Psychiatry 1999;60: 574-579